Royalty Pharma plc (NASDAQ:RPRX) saw an upside of 1.21% to $30.97 after adding $0.37 on Monday. The 5-day average trading volume is 1,528,047 shares of the company’s common stock. It has gained $31.55 in the past week and touched a new high 1 time within the past 5 days. An average of 1,801,147 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,441,319.
RPRX’s 1-month performance is 3.20% or $0.98 on its low of $29.89 reached on 07/10/23. The company’s shares have touched a 52-week low of $29.20 and high of $44.66, with the stock’s rally to the 52-week high happening on 01/03/23. YTD, RPRX has lost -21.63% or -$8.53 and has reached a new high 1 time. However, the current price is down -30.65% from the 52-week high price.
Insider Transactions
RPRX stock investors last saw insider trading activity on Jul 13.Coyne Terrance P. (EVP & CFO) most recently sold 37,500 shares at $30.93 per share on Jul 13. This transaction cost the insider $1,159,958. EVP & CFO, Coyne Terrance P., sold 37,500 shares at a price of $31.07 on Jul 12. Then, on Jun 06, EVP, Investments & CLO Lloyd George W. sold 79,099 shares at a price of $33.82 per share. This transaction amounted to $2,674,796.
Valuation Metrics
RPRX stock has a beta of 0.39. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 7.97 while the price-to-book (PB) in the most recent quarter is 2.32, with the price to cash flow ratio at 544.84.
Royalty Pharma plc’s quick ratio for the period ended March 30 was 2.40, with the current ratio over the same period at 2.40. As well, the company’s long term debt to equity for the quarter ending March 30 was 1.03, while the total debt to equity was 1.20. The firm’s gross profit as reported stood at $1.93 billion against revenue of $2.24 billion.
Earnings Surprise
For the quarterly period ending March 30 this year, Royalty Pharma plc’s cash and short-term investments amounted to $2.5 million against total debt of $7.12 billion. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 84.81% to $340.76 million, while revenue of -$456.08 million was 233.84% off the previous quarter. Analysts expected RPRX to announce $1.27 per share in earnings in its latest quarter, but it posted $1.6, representing a 26.00% surprise. EBITDA for the quarter stood at more than $484.3 million. RPRX stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 7.25 billion, with total debt at $7.12 billion. Shareholders hold equity totaling $607.14 million.
Let’s look briefly at Royalty Pharma plc (RPRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 51.75% to suggest the stock is trending Neutral, with historical volatility in this time period at 13.32%.
The stock’s 5-day moving average is $30.75, reflecting a -1.26% or -$0.39 change from its current price. RPRX is currently trading +3.11% above its 20-day SMA, -6.70% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -3.83% and SMA200 by-26.26%.
Stochastic %K and %D was 32.56% and 30.72% and the average true range (ATR) pointed at 0.49. The RSI (14) points at 48.84%, while the 14-day stochastic is at 52.52% with the period’s ATR at 0.52. The stock’s 9-day MACD Oscillator is pointing at -0.23 and -0.29 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for RPRX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate RPRX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 8 have offered a “buy” rating.
What is RPRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $42.00 and a high of $60.00, with their median price target at $48.90. Looking at these predictions, the average price target given by analysts is for Royalty Pharma plc (RPRX) stock is $49.23.
